ImmuPharma (LON:IMM) Shares Down 19.5% – Time to Sell?

ImmuPharma plc (LON:IMM)’s stock price dropped 19.5% during mid-day trading on Thursday . The company traded as low as GBX 3.21 and last traded at GBX 3.21. Approximately 1,367,494 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 2,443,213 shares. The stock had previously closed at GBX 3.98.

ImmuPharma Trading Down 19.5%

The firm has a market capitalization of £20.00 million, a price-to-earnings ratio of -8.66 and a beta of 3.01. The firm has a fifty day moving average price of GBX 3.85 and a 200 day moving average price of GBX 4.33.

ImmuPharma (LON:IMM) last released its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 633.14%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.